Kalaris Therapeutics (KLRS) Cash & Equivalents (2019 - 2026)

Kalaris Therapeutics' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $104.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 3.9% year-over-year to $104.9 million; the TTM figure through Mar 2026 stood at $104.9 million (up 3.9% YoY), while the FY2025 annual figure was $98.1 million, up 9617.94% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $104.9 million, up from $98.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $197.0 million in Q2 2023, with the low at $77000.0 in Q3 2025.
• The 5-year median for Cash & Equivalents is $95.6 million (2023), against an average of $76.8 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 98.88% in 2024, then jumped 9617.94% in 2025.
• Kalaris Therapeutics' Cash & Equivalents stood at $106.1 million in 2022, then retreated by 15.05% to $90.1 million in 2023, then sank by 98.88% to $1.0 million in 2024, then surged by 9617.94% to $98.1 million in 2025, then advanced by 6.98% to $104.9 million in 2026.
• Business Quant data shows KLRS's Cash & Equivalents at $104.9 million in Q1 2026, $98.1 million in Q4 2025, and $77000.0 in Q3 2025.